Satsuma Pharmaceuticals, Inc. (STSA) |
| 1.1 0 (0%) 06-07 16:00 |
| Open: | 1.11 |
| High: | 1.1 |
| Low: | 1.1 |
| Volume: | 1,826,389 |
| Market Cap: | 36(M) |
| PE Ratio: | -0.55 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 8.08 |
| 52w Low: | 0.59 |
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate. Currently, STS101 is progressing through its pivotal SUMMIT Phase 3 efficacy trials and is designed for self-administration via a specialized, pre-filled, single-use nasal delivery device. Established in 2016, the company maintains its headquarters in South San Francisco, California.
Financials
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Company news
Mon, 13 Jul 2026
If You Invested $1,000 in Satsuma Pharmaceuticals, Inc. (STSA) - Stock Titan
Wed, 30 Apr 2025
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine - PR Newswire
Sun, 16 Apr 2023
SNBL to Acquire Satsuma Pharmaceuticals - GlobeNewswire
Tue, 15 Mar 2022
Satsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights - GlobeNewswire
Tue, 14 Sep 2021
Rite Aid - RAD - Stock Price & News - The Motley Fool
Wed, 28 Jul 2021
Satsuma launches Phase 3 trial for acute migraine drug - drugdiscoverytrends.com
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
